PEER-REVIEWED ARTICLE

Palliative care during the end-of-life period in an intensive care unit - a quality assurance project

<u>Kari Fjøsne</u>

Intensivsykepleier Hovedintensiv, Klinikk for anestesi- og intensivmedisin, St. Olavs hospital

Pål Klepstad

Avdelingssjef og professor

Hovedintensiv, Klinikk for anestesi- og intensivmedisin, St. Olavs hospital og Institutt for sirkulasjon og bildediagnostikk, Fakultet for medisin og helsevitenskap, Norges teknisk-naturvitenskapelige universitet, Trondheim

Kari Hanne Gjeilo

Førsteamanuensis og forskningssykepleier

Institutt for samfunnsmedisin og sykepleie, Fakultet for medisin og helsevitenskap NTNU Trondheim og Klinikk for hjertemedisin og Klinikk for thoraxkirurgi, St. Olavs hospital

Intensive care unit Palliative care Quantiative study

Sykepleien Forskning 2023;18(92261):e-92261 DOI: <u>10.4220/Sykepleienf.2023.92261en</u>

Abstract

Background: The Norwegian Directorate of Health has issued national clinical guidelines for palliative care during the end-of-life period. Many dying patients in intensive care have a high symptom burden. To ensure that palliative care is of high quality, it is necessary to investigate whether clinical practice is in line with the applicable recommendations.

Objective: The objective was to examine documented practice of palliative care during the end-of-life period for patients in an intensive care unit. We also wanted to investigate whether practice was in accordance with the national clinical guidelines.

Method: The study is a quality assurance project with a retrospective review of patient medical records. We carried out descriptive, quantitative analyses. The sample consisted of adult patients over the age of 18 who died in an intensive care unit at a university hospital in Norway in 2021.

Results: A total of 88 patients died. Of these, 69 were included in the study. The median time between the withdrawal of life-sustaining interventions and death was twelve minutes. There was a documented nursing care plan for the withdrawal of interventions for 13% of the patients. There was no documented pain score for the patients who were conscious. Use of the Critical Care Pain Observation Tool (CPOT) was documented for 16.7% of the patients who had a decreased level of consciousness, 58.3% of the comatose patients and 44.7% of the sedated patients. None of the patients who were conscious or comatose received a continual infusion of symptom relief medication, only bolus doses. Sedated patients received an infusion of opioids and/or sedatives. There were no documented conversations with the conscious patients. Conversations with patients' families were documented by 94.2% of the doctors and 65.2% of the intensive care unit nurses.

Conclusion: The study shows that documentation of pain assessment and nursing care plans for dying patients in intensive care was inadequate. Documentation of information provided to patients was also inadequate.

Introduction

The purpose of intensive care treatment is to maintain vital organ function in critically ill patients. Even though patients receive advanced intensive medical treatment, there are many who die (1). In 2021, 10.2% of patients in Norwegian intensive care units (ICUs) died, and this figure has changed little over the past five years (2).

Palliative care for patients during the end-of-life period in ICU is therefore a relevant area of competence. To ensure that patients' needs for symptom management are met, ICU nurses must have knowledge and competence within palliative care (3).

International literature shows that ICU patients during the end-of-life period can suffer from many distressing symptoms, of which pain, anxiety and dyspnoea are the most common (1, 4, 5). However, symptom management is often inadequate (6). Implementation of nursing care plans and protocols for palliative care in ICU results in the increased use of pain relief and sedative medications and therefore a lower symptom burden (1, 7). Nevertheless, there is a lack of guidelines and nursing care plans for palliative care in ICU, and there is considerable variation as to whether these are used in clinical practice (5, 8).

In Norway, there are no national guidelines for palliative care in ICUs. However, the Norwegian Directorate of Health has issued national clinical guidelines for palliative care during the end-of-life period. The clinical guidelines are intended to help ensure that patients receive sound professional and evidence-based palliative care (9). The national clinical guidelines indicate that different measures for managing, for example, pain, dyspnoea, anxiety and agitation should always be assessed. Suggested measures and the anticipated need of symptom relief medications should be documented in a nursing care plan, and regular assessments of the patient's symptom burden must be carried out. In addition, communication with patients and their families must be ensured (9).

The national clinical guidelines provide general advice, and the Norwegian regional health authorities are responsible for ensuring that the guidelines are followed (9). The health service has a duty to carry out quality improvement work. It is necessary to examine whether clinical practice is in line with relevant recommendations (10, 11).

The objective of this study was to describe documented practice for pain assessment, medication-based symptom management, nursing care plans and communication with patients and their families during the end-of-life period in ICUs. We also wanted to investigate whether the practice is in accordance with the national clinical guidelines for palliative care during the end-of-life period. We used the following research question as a starting point:

'What is the current documented practice of palliative care for patients during the end-oflife period in an ICU?'

Method

Design

The study's design is a retrospective observational study (12) with a review of patient medical records in a time line from the withdrawal of life-sustaining interventions until the patient's death. The study was also a quality assurance project at an ICU in which the objective was to summarise current documented practice. The results were intended to evaluate the quality of current practice (13).

Sample

The sample consisted of patients over the age of 18 who died in the main ICU at St. Olav's University Hospital in 2021, regardless of the cause of admission. Life-sustaining interventions were withdrawn or a decision not to increase the level of treatment was made before death. Patients who were organ donors and patients who died during operations or despite active efforts to resuscitate them, such as cardiopulmonary resuscitation in the case of cardiac arrest, were excluded from the study.

Data collection method

The data were collected from electronic anaesthesia and ICU records and electronic patient medical records. The variables that were used in data collection were based on the Norwegian Directorate of Health's national clinical guidelines for palliative care during the end-of-life period (9). The variables were as follows: 'age', 'gender', 'cause of admission', 'number of days between admission and death', 'time from withdrawal of interventions until death', 'consciousness at time of withdrawal of interventions' and 'respiratory support at time of withdrawal of interventions'.

In relation to pain assessment, we investigated whether there was documented use of the assessment tools Numeric Rating Scale 0–10 (NRS) or Critical Care Pain Observation Tool (CPOT) (14). Local routines for pain assessment in the ICU indicate that if the patient is responsive, NRS is used. For patients who are unable to communicate, CPOT is registered regularly once per shift as well as when required, for example, when repositioning the patient.

We examined whether an individual nursing care plan had been documented. A nursing care plan contains measures for symptom management and a plan for the anticipated need for medication that might arise (9).

Furthermore, we examined which symptom relief medications the patient received for pain, gurgling in the lower respiratory tract, anxiety and agitation, as well as doses of medication before and after the withdrawal of interventions. The withdrawal of interventions is defined as the termination of life-sustaining treatment. The infusion speed of medication was registered 15 minutes prior to the withdrawal of interventions and immediately before the documented time of death.

In order to assess communication, we examined whether the provision of information regarding the course of the illness and prognosis to patients who were conscious had been documented. We also examined whether a conversation with the patient's family had been documented by the ICU nurse and doctor, and whether the patient's family was present at the time of withdrawal of interventions.

There were no recorded assessments of anxiety and agitation. The Richmond Agitation-Sedation Scale (RASS) is a tool for measuring the level of sedation, in which anxiety and agitation are factors (15). In the St Olav's University Hospital ICU, this is used solely to measure the depth of sedation.

The patients were categorised in four groups, based on their documented level of consciousness: 1) sedated patients, 2) comatose non-sedated patients, 3) patients with a decreased level of consciousness, and 4) conscious patients.

Before commencing data collection, we pilot tested variables (12) on four patients. A data review was conducted by the first author in February–March 2022. Cases in which there was doubt concerning the categorisation of data and the extent to which treatment followed the guidelines were discussed individually with the second author.

Data analysis

We carried out descriptive analyses using the analysis software Statistical Package for the Social Sciences (SPSS), version 27 (16). Descriptive analysis is used to describe and summarise the data. Categoric variables are presented as absolute numbers (n) and percentages (%).

Continuous variables are presented with central tendencies and dispersion. Normally distributed data are presented as averages and standard deviations (SD), and non-normally distributed data with median and interquartile range (IQR) (12).

Ethical considerations

This project was a retrospective study and did not alter or affect patient treatment. The project was an internal quality assurance project that was outside the mandate of the Regional Committee for Medical and Health Research Ethics (REK), and did not come under the substantive scope of the Health Research Act, see sections 2 and 4.

The project was carried out with support from hospital management in accordance with the requirements for quality assurance in the Health Personnel Act, see section 26 (17). The head of the project filled in a self-assessment form in conjunction with the Data Protection Impact Assessment (DPIA). The hospital's research committee assessed and approved the project in line with the hospital's routines for quality assurance projects and the protection of personal data. We followed the hospital's routines for safe storage in a dedicated file area.

Results

Description of sample

A total of 88 patients died. Of those, we excluded eleven patients who were organ donors and eight patients who died during operations or after active efforts to resuscitate them. We analysed the medical records of 69 patients. The majority of the patients were men (73.9%), and the most frequent causes of admission were respiratory failure (23.2%) and circulatory failure (23.2%) (Table 1).

As shown in Table 1, the median time from withdrawal of interventions until death was 12 minutes and the number of days between admission and death was 2.9 (median). Most of the patients were over 60 years of age (79.7%) and only four of the patients were under the age of 39 (5.8%). A majority of the patients were sedated (68.1%).

	Median (IQR)
Time (minutes) from withdrawal of interventions until death	12 (8–31)
Number of days between admittance and death	2.9 (0.7–7.6)

	Average ± SD
Age (years)	67.5 ± 14.3

		n (%)
Age group	Over 80 60–79 40–59 18–39	11 (15.9) 44 (63.8) 10 (14.5) 4 (5.8)
Men Women		51 (73.9) 18 (26.1)
Cause of admission	Respiratory failure Circulatory failure Sepsis Post-operative complications Trauma Neurological trauma/disease Other	16 (23,2) 16 (23.2) 13 (18.8) 8 (11.6) 4 (5.8) 4 (5.8) 8 (11.6)
Consciousness at time of withdrawal of interventions	Conscious Decreased level of consciousness Comatose (non-sedated) Sedated	4 (5.8) 6 (8.7) 12 (17.4) 47 (68.1)
Respiratory support at time of withdrawal of interventions	Intubated Tracheostomy Non-invasive ventilation Optiflow Oxygen mask/nasal catheter	54 (78.3) 2 (2.9) 4 (5.8) 3 (4.3) 6 (8.7)

Normally distributed data are presented as averages and non-normally distributed data are presented as the median. Abbreviations: IQR = interquartile range, SD = standard deviation.

Nursing care plans and symptom assessment

There was a written nursing care plan for the withdrawal of life-sustaining interventions for 13% of the patients (n = 69). Pain rated from 0–10 using the self-reporting assessment tool NRS was not documented in the case of the four conscious patients.

Pain assessment using CPOT for patients with a reduced ability to communicate was documented in 16.7% of the patients who had a decreased level of consciousness, in 58.3% of the comatose patients and in 44.7% of the sedated patients.

The use of CPOT as required was not documented in relation to any of the patients. Analgesics were administered to patients without documented pain assessment as frequently as to patients with documented pain assessment (Table 2). Table 2. NRS or CPOT related to level of consciousness and correspondence between documented NRS or CPOT and analgesics

Documented use of pain assessment tools		n (%)
Conscious (n = 4)	NRS	0
Decreased level of consciousness (n = 6)	CPOT	1 (16.7)
	CPOT as required	0
Comatose (non-sedated) (n = 12)	СРОТ	7 (58.3)
	CPOT as required	0
Sedated (n = 47)	СРОТ	21 (44.7)
	CPOT as required	0

Correspondence between documented NRS/CPOT and analgesics for all patients (n = 69)	n (%)
NRS/CPOT not documented, analgesics administered	32 (46.4)
NRS/CPOT not documented, analgesics not administered	8 (11.6)
NRS/CPOT documented, analgesics administered	22 (31.9)
NRS/CPOT documented, analgesics not administered	7 (10.1)

Abbreviations: CPOT = Critical Care Pain Observation Tool. Pain assessment tool for patients who are unable to communicate. Registered regularly once per shift as well as when required, for example, when repositioning the patient. NRS = Numeric Rating Scale 0-10. Self-reporting pain assessment tool for patients who are able to communicate.

Symptom relief medications

None of the conscious patients received a continual infusion of symptom relief medications, but three of the four conscious patients received bolus doses of opioids (Table 3).

As shown in Table 3, one of the patients who had a decreased level of consciousness was given opioids, one was given paracetamol and one patient was given diazepam after the withdrawal of interventions. None of the comatose patients received continual infusions with symptom relief medications (Table 3).

Table 3 shows that sedated patients (n = 47) received an infusion of opioids and/or sedatives. The dose before and after the withdrawal of life-sustaining interventions was approximately the same, except in the case of one patient who only received remiferitanil and another who received an infusion of morphine in addition to other analgesics. Roughly a quarter and a tenth of the sedated patients were given bolus doses of analgesics and sedatives, respectively, after the withdrawal of life-sustaining interventions.

Medication		n (%)

Table 3 Use of symptom relief medications

MorphineBolus dose after withdrawal of interventions*2 (50)4 ± 1.4Decreased level of consciousness (n = 6):Decreased level of consciousness (n = 6):Infusion, dose before withdrawal of interventions*3 (50)0.75 ± 0.4DexmedetomidineInfusion, dose after withdrawal of interventions*3 (50)0.75 ± 0.40.81 ± 0.5OxyNormBolus dose after withdrawal of interventions*1 (16.6)1.251.25ParacetamolDose after withdrawal of interventions*1 (16.6)50 ± 42.4DiazepamBolus dose after withdrawal of interventions*2 (16.6)50 ± 42.4OxyNormBolus dose after withdrawal of interventions*1 (8.3)37MorphineBolus dose after withdrawal of interventions*1 (8.3)0.2PropofolBolus dose after withdrawal of interventions*1 (8.3)0.2ParacetamolDose after withdrawal of interventions*1 (8.3)0.2DiazepamBolus dose after withdrawal of interventions*1 (8.3)0.2ParacetamolDose after withdrawal of interventions*1 (8.3)0.2DiazepamBolus dose after withdrawal of interventions*1 (8.3)0.2Sedated patients (n = 47):Infusion, dose before withdrawal of interventions*1 (8.3)0.2PropofolInfusion, dose after withdrawal of interventions*2 (16.6)0.18 ± 0.1Disus dose after withdrawal of interventions*1 (8.3)0.2Sedated patients (n = 47):Infusion, dose before withdrawal of interventions*2 (0.6)0.18 ± 0.1	OxyNorm	Bolus dose after withdrawal of interventions ^a	1 (25)	2.5
Decreased level of consciousness (n = 6):Intusion, dose before withdrawal of interventions ^b 3 (50)0.75 ± 0.4DexmedetomidineInfusion, dose after withdrawal of interventions ^b 3 (50)0.81 ± 0.5OxyNormBolus dose after withdrawal of interventions ^a 1 (16.6)125ParacetamolDose after withdrawal of interventions ^a 1 (16.6)7.5DiazepamBolus dose after withdrawal of interventions ^a 1 (16.6)50 ± 42.4OxyNormBolus dose after withdrawal of interventions ^a 1 (16.6)50 ± 42.4OxyNormBolus dose after withdrawal of interventions ^a 1 (8.3)37MorphineBolus dose after withdrawal of interventions ^a 1 (8.3)0.2ParacetamolDose after withdrawal of interventions ^a 1 (8.3)0.2ParacetamolDose after withdrawal of interventions ^a 2 (16.6)1000DiazepamBolus dose after withdrawal of interventions ^a 2 (16.6)10.8 ± 0.1PropofolInfusion, dose before withdrawal of interventions ^a 2 (16.6)0.18 ± 0.1Disk dose after withdrawal of interventions ^a 2 (16.6)0.222.4 ± 1Infusion, dose before withdrawal of interventions ^a 2 (16.6)0.18 ± 0.1Disk dose after withdrawal of interventions ^a 3 (6.3)	Morphine	Bolus dose after withdrawal of interventions ^a	2 (50)	4 ± 1.4
DexmedetomidineInfusion, dose before withdrawal of interventions ^b 3 (50)0.75 ± 0.4OxyNormBolus dose after withdrawal of interventions ^b 3 (50)0.81 ± 0.5OxyNormBolus dose after withdrawal of interventions ^a 1 (16.6)1.25ParacetamolDose after withdrawal of interventions ^a 1 (16.6)1.000DiazepamBolus dose after withdrawal of interventions ^a 1 (16.6)7.5Comatose patients (n = 12): </td <td>Decreased level of consciousness (n = 6):</td> <td>Decreased level of consciousness (n = 6):</td> <td></td> <td></td>	Decreased level of consciousness (n = 6):	Decreased level of consciousness (n = 6):		
Infusion, dose after withdrawal of interventions ^b 3 (50)0.81 ± 0.5OxyNormBolus dose after withdrawal of interventions ^a 1 (16.6)1.25ParacetamolDose after withdrawal of interventions ^a 1 (16.6)1.000DiazepamBolus dose after withdrawal of interventions ^a 1 (16.6)7.5Comatose patients (n = 12):PropofolBolus dose after withdrawal of interventions ^a 2 (16.6)50 ± 42.4OxyNormBolus dose after withdrawal of interventions ^a 1 (8.3)37MorphineBolus dose after withdrawal of interventions ^a 3 (25)25.8 ± 29.6FentanylBolus dose after withdrawal of interventions ^a 1 (8.3)0.2ParacetamolDose after withdrawal of interventions ^a 2 (16.6)1000DiazepamBolus dose after withdrawal of interventions ^a 2 (16.6)7.5 ± 3.5RobinulBolus dose after withdrawal of interventions ^a 2 (16.6)0.18 ± 0.1Infusion, dose after withdrawal of interventions ^a 1 (8.3)0.2PrentanylInfusion, dose before withdrawal of interventions ^a 40 (85)0.18 ± 0.1Infusion, dose after withdrawal of interventions ^a 9 (19.2)0.23 ± 0.2PropofolInfusion, dose after withdrawal of interventions ^a 9 (19.2)0.23 ± 0.2PropofolInfusion, dose after withdrawal of interventions ^a 1 (2.1)0.1Infusion, dose after withdrawal of interventions ^a 1 (2.1)0.23 (5.3)PropofolInfusion, dose after withdrawal of interventions ^a 1 (2.1)<	Dexmedetomidine	Infusion, dose before withdrawal of interventions ^b	3 (50)	0.75 ± 0.4
OxyNormBolus dose after withdrawal of interventions*1 (16.6)1.25ParacetamolDose after withdrawal of interventions*1 (16.6)1000DiazepamBolus dose after withdrawal of interventions*1 (16.6)7.5Comatose patients (n = 12): </td <td></td> <td>Infusion, dose after withdrawal of interventions^b</td> <td>3 (50)</td> <td>0.81 ± 0.5</td>		Infusion, dose after withdrawal of interventions ^b	3 (50)	0.81 ± 0.5
Paracetamol DiazepamDose after withdrawal of interventions*1 (16.6)1000DiazepamBolus dose after withdrawal of interventions*1 (16.6)7.5Comatose patients (n = 12):FropofolBolus dose after withdrawal of interventions*2 (16.6)50 ± 42.4OxyNormBolus dose after withdrawal of interventions*1 (8.3)37MorphineBolus dose after withdrawal of interventions*3 (25)25.8 ± 29.6FentanylBolus dose after withdrawal of interventions*1 (8.3)0.2ParacetamolDose after withdrawal of interventions*2 (16.6)1000DiazepamBolus dose after withdrawal of interventions*2 (16.6)7.5 ± 3.5RobinulBolus dose after withdrawal of interventions*2 (16.6)7.5 ± 3.5RobinulBolus dose after withdrawal of interventions*1 (8.3)0.2Sedated patients (n = 47):FentanylInfusion, dose before withdrawal of interventions*40 (85)0.18 ± 0.1Infusion, dose after withdrawal of interventions*9 (19.2)0.23 ± 0.22.42 ± 1Bolus dose after withdrawal of interventions*20 (42.6)2.42 ± 1Infusion, dose after withdrawal of interventions*10 (2.1)0.1MorphineInfusion, dose after withdrawal of interventions*1 (2.1)0.5PropofolInfusion, dose after withdrawal of interventions*1 (2.1)0.5MichanalInfusion, dose after withdrawal of interventions*1 (2.1)0.1MorphineInfusion, dose after withdrawal of interventions* <t< td=""><td>OxyNorm</td><td>Bolus dose after withdrawal of interventions^a</td><td>1 (16.6)</td><td>1.25</td></t<>	OxyNorm	Bolus dose after withdrawal of interventions ^a	1 (16.6)	1.25
DiazepamBolus dose after withdrawal of interventions ^a 1 (16.6)7.5Comatose patients (n = 12):Bolus dose after withdrawal of interventions ^a 2 (16.6)50 ± 42.4OxyNormBolus dose after withdrawal of interventions ^a 1 (8.3)37MorphineBolus dose after withdrawal of interventions ^a 1 (8.3)37ParacetamolDose after withdrawal of interventions ^a 3 (25)25.8 ± 29.6ParacetamolDose after withdrawal of interventions ^a 2 (16.6)1000DiazepamBolus dose after withdrawal of interventions ^a 2 (16.6)7.5 ± 3.5RobinulBolus dose after withdrawal of interventions ^a 2 (16.6)7.5 ± 3.5RobinulBolus dose after withdrawal of interventions ^a 1 (8.3)0.2Sedated patients (n = 47):Infusion, dose before withdrawal of interventions ^a 40 (85)0.18 ± 0.1Infusion, dose after withdrawal of interventions ^a 9 (19.2)0.23 ± 0.2PropofolInfusion, dose after withdrawal of interventions ^a 9 (19.2)0.23 ± 0.2PropofolInfusion, dose after withdrawal of interventions ^a 19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventions ^a 1 (2.1)0.50.1MorphineInfusion, dose before withdrawal of interventions ^a 1 (2.1)0.5MorphineInfusion, dose before withdrawal of interventions ^a 1 (2.1)0.5MorphineInfusion, dose after withdrawal of interventions ^a 1 (2.1)0.5MorphineInfusion, dose after withdrawal of interventi	Paracetamol	Dose after withdrawal of interventions ^a	1 (16.6)	1000
Comatose patients (n = 12):Bolus dose after withdrawal of interventions*2 (16.6)50 \pm 42.4PropofolBolus dose after withdrawal of interventions*1 (8.3)37MorphineBolus dose after withdrawal of interventions*1 (8.3)37ParacetamolDose after withdrawal of interventions*1 (8.3)0.2ParacetamolDose after withdrawal of interventions*2 (16.6)1000DiazepamBolus dose after withdrawal of interventions*2 (16.6)7.5 \pm 3.5RobinulBolus dose after withdrawal of interventions*2 (16.6)0.2Sedated patients (n = 47):Fentanyl1 (8.3)0.2FentanylInfusion, dose before withdrawal of interventions*40 (85)0.18 \pm 0.1Bolus dose after withdrawal of interventions*9 (19.2)0.23 \pm 0.2PropofolInfusion, dose before withdrawal of interventions*9 (19.2)0.23 \pm 0.2PropofolInfusion, dose after withdrawal of interventions*19 (40.4)2.23 \pm 1.2Bolus dose after withdrawal of interventions*10 (2.1)0.510.4 \pm 48.9RemifentanilInfusion, dose before withdrawal of interventions*1 (2.1)0.5MorphineInfusion, dose before withdrawal of interventions*1 (2.1)0.1MorphineInfusion, dose after withdrawal of interventions*1 (2.1)0.5MidazolamInfusion, dose before withdrawal of interventions*1 (2.1)0.5MorphineInfusion, dose after withdrawal of interventions*1 (2.1)0.5Mi	Diazepam	Bolus dose after withdrawal of interventions ^a	1 (16.6)	7.5
Comatose patients (n = 12):For popoloBolus dose after withdrawal of interventions#2 (16.6)50 ± 42.4OxyNormBolus dose after withdrawal of interventions#1 (8.3)37MorphineBolus dose after withdrawal of interventions#3 (25)25.8 ± 29.6FentanylBolus dose after withdrawal of interventions#3 (25)25.8 ± 29.6ParacetamolDose after withdrawal of interventions#1 (8.3)0.2DiazepamBolus dose after withdrawal of interventions#2 (16.6)1000DiazepamBolus dose after withdrawal of interventions#2 (16.6)7.5 ± 3.5RobinulBolus dose after withdrawal of interventions#1 (8.3)0.2Sedated patients (n = 47):Infusion, dose before withdrawal of interventions*40 (85)0.18 ± 0.1Infusion, dose after withdrawal of interventions*9 (19.2)0.23 ± 0.20.23 ± 0.2PropofolInfusion, dose before withdrawal of interventions*9 (19.2)0.23 ± 0.2PropofolInfusion, dose after withdrawal of interventions*19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventions*19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventions*10.0511Infusion, dose before withdrawal of interventions*10.10.5MorphineInfusion, dose before withdrawal of interventions*10.1MorphineInfusion, dose after withdrawal of interventions*10.6)10.85 ± 6.8AlfentanilBolus dose after withdrawal of interventions*10.10.5<				
PropofolBolus dose after withdrawal of interventions ^a 2 (16.6)50 ± 42.4OxyNormBolus dose after withdrawal of interventions ^a 1 (8.3)37MorphineBolus dose after withdrawal of interventions ^a 3 (25)25.8 ± 29.6FentanylBolus dose after withdrawal of interventions ^a 1 (8.3)0.2ParacetamolDose after withdrawal of interventions ^a 2 (16.6)1000DiazepamBolus dose after withdrawal of interventions ^a 2 (16.6)7.5 ± 3.5RobinulBolus dose after withdrawal of interventions ^a 1 (8.3)0.2Sedated patients (n = 47):Infusion, dose before withdrawal of interventions ^c 40 (85)0.18 ± 0.1Infusion, dose after withdrawal of interventions ^c 40 (85)0.18 ± 0.10.2 ± 2.4 ± 1Infusion, dose after withdrawal of interventions ^c 40 (85)0.23 ± 0.20.23 ± 0.2PropofolInfusion, dose before withdrawal of interventions ^c 19 (40.4)2.23 ± 1.20.23 ± 0.2Bolus dose after withdrawal of interventions ^c 19 (40.4)2.23 ± 1.20.5± 4.8.9RemifentanilInfusion, dose before withdrawal of interventions ^c 1 (2.1)0.051.1MorphineInfusion, dose after withdrawal of interventions ^c 1 (2.1)0.10.1MorphineInfusion, dose after withdrawal of interventions ^c 1 (2.1)0.51.8.8AlfentanilBolus dose after withdrawal of interventions ^c 1 (2.1)0.051.8.8 ± 6.8AlfentanilBolus dose after withdrawal of intervention	Comatose patients (n = 12):			
OxyNormBolus dose after withdrawal of interventions*1 (8.3)37MorphineBolus dose after withdrawal of interventions*3 (25)25.8 ± 29.6FentanylBolus dose after withdrawal of interventions*1 (8.3)0.2ParacetamolDose after withdrawal of interventions*2 (16.6)1000DiazepamBolus dose after withdrawal of interventions*2 (16.6)7.5 ± 3.5RobinulBolus dose after withdrawal of interventions*1 (8.3)0.2Sedated patients (n = 47):Infusion, dose before withdrawal of interventions*40 (85)0.18 ± 0.1FentanylInfusion, dose before withdrawal of interventions*40 (85)0.18 ± 0.1Infusion, dose after withdrawal of interventions*9 (19.2)0.23 ± 0.2PropofolInfusion, dose before withdrawal of interventions*9 (19.2)0.23 ± 0.2PropofolInfusion, dose after withdrawal of interventions*19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventions*19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventions*1 (2.1)0.05Infusion, dose before withdrawal of interventions*1 (2.1)0.1MorphineInfusion, dose after withdrawal of interventions*1 (2.1)30Bolus dose after withdrawal of interventions*1 (2.1)30Bolus dose after withdrawal of interventions*1 (2.1)30MorphineInfusion, dose after withdrawal of interventions*1 (2.1)2.5MidazolamInfusion, dose after withdrawal of interventions*1	Propofol	Bolus dose after withdrawal of interventions ^a	2 (16.6)	50 ± 42.4
MorphineBolus dose after withdrawal of interventions ^a 3 (25)25.8 ± 29.6FentanylBolus dose after withdrawal of interventions ^a 1 (8.3)0.2ParacetamolDose after withdrawal of interventions ^a 2 (16.6)1000DiazepamBolus dose after withdrawal of interventions ^a 2 (16.6)7.5 ± 3.5RobinulBolus dose after withdrawal of interventions ^a 2 (16.6)7.5 ± 3.5RobinulBolus dose after withdrawal of interventions ^a 1 (8.3)0.2Sedated patients (n = 47):Infusion, dose before withdrawal of interventions ^c 40 (85)0.18 ± 0.1FentanylInfusion, dose before withdrawal of interventions ^c 40 (85)0.18 ± 0.1Bolus dose after withdrawal of interventions ^c 40 (85)0.18 ± 0.1Bolus dose after withdrawal of interventions ^c 9 (19.2)0.23 ± 0.2PropofolInfusion, dose before withdrawal of interventions ^c 20 (42.6)2.42 ± 1Infusion, dose after withdrawal of interventions ^c 19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventions ^c 19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventions ^c 1 (2.1)0.5Infusion, dose before withdrawal of interventions ^e 1 (2.1)0.5Infusion, dose after withdrawal of interventions ^e 1 (2.1)30Bolus dose after withdrawal of interventions ^e 1 (2.1)30Bolus dose after withdrawal of interventions ^a 1 (3.1)10.68 ± 6.8AlfentanilBolus dose after withdrawal of interventions ^a 1 (3	OxyNorm	Bolus dose after withdrawal of interventions ^a	1 (8.3)	37
FentanylBolus dose after withdrawal of interventions*1 (8.3)0.2ParacetamolDose after withdrawal of interventions*2 (16.6)1000DiazepamBolus dose after withdrawal of interventions*2 (16.6)7.5 ± 3.5RobinulBolus dose after withdrawal of interventions*1 (8.3)0.2Sedated patients (n = 47):Infusion, dose before withdrawal of interventions40 (85)0.18 ± 0.1FentanylInfusion, dose before withdrawal of interventions40 (85)0.18 ± 0.1Bolus dose after withdrawal of interventions40 (85)0.18 ± 0.1Bolus dose after withdrawal of interventions9 (19.2)0.23 ± 0.2PropofolInfusion, dose before withdrawal of interventions20 (42.6)2.42 ± 1Infusion, dose after withdrawal of interventions19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventions19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventions1 (2.1)0.05Infusion, dose before withdrawal of interventions1 (2.1)0.1MorphineInfusion, dose before withdrawal of interventions1 (2.1)30Bolus dose after withdrawal of interventions*5 (10.6)10.85 ± 6.8AlfentanilBolus dose after withdrawal of interventions*1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventions*1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventions*1 (2.1)2.5Bolus dose after withdrawal of interventions*1 (2.1)2.5 <tr< td=""><td>Morphine</td><td>Bolus dose after withdrawal of interventions^a</td><td>3 (25)</td><td>25.8 ± 29.6</td></tr<>	Morphine	Bolus dose after withdrawal of interventions ^a	3 (25)	25.8 ± 29.6
ParacetamolDose after withdrawal of interventions*2 (16.6)1000DiazepamBolus dose after withdrawal of interventions*2 (16.6)7.5 ± 3.5RobinulBolus dose after withdrawal of interventions*1 (8.3)0.2Sedated patients (n = 47):Infusion, dose before withdrawal of interventions°40 (85)0.18 ± 0.1FentanylInfusion, dose after withdrawal of interventions°40 (85)0.18 ± 0.1Bolus dose after withdrawal of interventions°40 (85)0.18 ± 0.1Bolus dose after withdrawal of interventions°9 (19.2)0.23 ± 0.2PropofolInfusion, dose before withdrawal of interventions°20 (42.6)2.42 ± 1Infusion, dose after withdrawal of interventions°19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventions°19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventions°1 (2.1)0.05Infusion, dose before withdrawal of interventions°1 (2.1)0.05Infusion, dose before withdrawal of interventions°1 (2.1)0.1MorphineInfusion, dose before withdrawal of interventions°1 (2.1)30Bolus dose after withdrawal of interventions°1 (2.1)30Bolus dose after withdrawal of interventions°1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventions°15 (31.9)10.06 ± 5.8Infusion, dose after withdrawal of interventions°16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventions°16 (34)10.19 ± 5.6Bolus dose after wi	Fentanyl	Bolus dose after withdrawal of interventions ^a	1 (8.3)	0.2
DiazepamBolus dose after withdrawal of interventions ^a 2 (16.6)7.5 ± 3.5RobinulBolus dose after withdrawal of interventions ^a 1 (8.3)0.2Sedated patients (n = 47):Image: Constraint of the second o	Paracetamol	Dose after withdrawal of interventions ^a	2 (16.6)	1000
RobinulBolus dose after withdrawal of interventions ^a 1 (8.3)0.2Sedated patients (n = 47):Infusion, dose before withdrawal of interventions ^c 40 (85)0.18 ± 0.1FentanylInfusion, dose after withdrawal of interventions ^c 40 (85)0.18 ± 0.1Bolus dose after withdrawal of interventions ^a 9 (19.2)0.23 ± 0.2PropofolInfusion, dose before withdrawal of interventions ^a 9 (19.2)0.23 ± 0.2PropofolInfusion, dose before withdrawal of interventions ^c 19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventions ^a 3 (6.3)64 ± 48.9RemifentanilInfusion, dose before withdrawal of interventions ^a 1 (2.1)0.05MorphineInfusion, dose before withdrawal of interventions ^a 1 (2.1)0.1MorphineInfusion, dose after withdrawal of interventions ^a 5 (10.6)10.85 ± 6.8AlfentanilBolus dose after withdrawal of interventions ^a 5 (10.6)10.05 ± 5.8MidazolamInfusion, dose before withdrawal of interventions ^a 1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventions ^a 1 (2.1)2.5DexmedetomidineInfusion, dose after withdrawal of interventions ^a 16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventions ^a 4 (8.5)6.75 ± 6DexmedetomidineInfusion, dose before withdrawal of interventions ^a 4 (8.5)1.2 ± 0.2	Diazepam	Bolus dose after withdrawal of interventions ^a	2 (16.6)	7.5 ± 3.5
Sedated patients (n = 47):Infusion, dose before withdrawal of interventions°40 (85)0.18 ± 0.1FentanylInfusion, dose after withdrawal of interventions°40 (85)0.18 ± 0.1Infusion, dose after withdrawal of interventions°40 (85)0.18 ± 0.1Bolus dose after withdrawal of interventions°9 (19.2)0.23 ± 0.2PropofolInfusion, dose before withdrawal of interventions°20 (42.6)2.42 ± 1Infusion, dose after withdrawal of interventions°19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventions°3 (6.3)64 ± 48.9RemifentanilInfusion, dose before withdrawal of interventions°1 (2.1)0.05Infusion, dose after withdrawal of interventions°1 (2.1)0.10.1MorphineInfusion, dose after withdrawal of interventions°01Infusion, dose after withdrawal of interventions°1 (2.1)30Bolus dose after withdrawal of interventions°1 (2.1)30Bolus dose after withdrawal of interventions°1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventions°15 (31.9)10.06 ± 5.8Infusion, dose after withdrawal of interventions°16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventions°16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventions°16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventions°4 (8.5)6.75 ± 6Bolus dose after withdrawal of interventions°4 (8.5)1.2 ± 0.2	Robinul	Bolus dose after withdrawal of interventions ^a	1 (8.3)	0.2
FentanylInfusion, dose before withdrawal of interventionse40 (85)0.18 ± 0.1Infusion, dose after withdrawal of interventionse40 (85)0.18 ± 0.1Bolus dose after withdrawal of interventionse9 (19.2)0.23 ± 0.2PropofolInfusion, dose before withdrawal of interventionse20 (42.6)2.42 ± 1Infusion, dose after withdrawal of interventionse19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventionse3 (6.3)64 ± 48.9RemifentanilInfusion, dose before withdrawal of interventionse1 (2.1)0.05MorphineInfusion, dose before withdrawal of interventionse01MorphineInfusion, dose after withdrawal of interventionse01MorphineInfusion, dose after withdrawal of interventionse1 (2.1)30Bolus dose after withdrawal of interventionse1 (2.1)3030MidazolamInfusion, dose before withdrawal of interventionse1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventionse15 (31.9)10.06 ± 5.8Infusion, dose after withdrawal of interventionse16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventionse16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventionse4 (8.5)6.75 ± 6DexmedetomidineInfusion, dose before withdrawal of interventionse4 (8.5)1.2 ± 0.2	Sedated patients (n = 47):			
Infusion, dose after withdrawal of interventionse40 (85)0.18 ± 0.1Bolus dose after withdrawal of interventionsa9 (19.2)0.23 ± 0.2PropofolInfusion, dose before withdrawal of interventionse20 (42.6)2.42 ± 1Infusion, dose after withdrawal of interventionse19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventionsa3 (6.3)64 ± 48.9RemifentanilInfusion, dose before withdrawal of interventionse1 (2.1)0.05Infusion, dose after withdrawal of interventionse1 (2.1)0.1MorphineInfusion, dose before withdrawal of interventionse0Infusion, dose after withdrawal of interventionse1 (2.1)30Bolus dose after withdrawal of interventionse1 (2.1)30MorphineInfusion, dose after withdrawal of interventionsa5 (10.6)10.85 ± 6.8AlfentanilBolus dose after withdrawal of interventionse1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventionse15 (31.9)10.06 ± 5.8Infusion, dose after withdrawal of interventionse16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventionse16 (34) </td <td>Fentanyl</td> <td>Infusion, dose before withdrawal of interventions^c</td> <td>40 (85)</td> <td>0.18 ± 0.1</td>	Fentanyl	Infusion, dose before withdrawal of interventions ^c	40 (85)	0.18 ± 0.1
PropofolBolus dose after withdrawal of interventionsa9 (19.2)0.23 ± 0.2PropofolInfusion, dose before withdrawal of interventionsc20 (42.6)2.42 ± 1Infusion, dose after withdrawal of interventionsc19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventionsa3 (6.3)64 ± 48.9RemifentanilInfusion, dose before withdrawal of interventionse1 (2.1)0.05Infusion, dose after withdrawal of interventionsc1 (2.1)0.1MorphineInfusion, dose before withdrawal of interventionsc0Infusion, dose after withdrawal of interventionsc01.2.1)MorphineInfusion, dose after withdrawal of interventionsc1 (2.1)Bolus dose after withdrawal of interventionsc1 (2.1)30Bolus dose after withdrawal of interventionsc1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventionsc15 (31.9)10.06 ± 5.8Infusion, dose after withdrawal of interventionsc16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventionsa4 (8.5)1.2 ± 0.2		Infusion, dose after withdrawal of interventions ^c	40 (85)	0.18 ± 0.1
PropofolInfusion, dose before withdrawal of interventionsc20 (42.6)2.42 ± 1Infusion, dose after withdrawal of interventionsc19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventionsa3 (6.3)64 ± 48.9RemifentanilInfusion, dose before withdrawal of interventionse1 (2.1)0.05Infusion, dose after withdrawal of interventionse1 (2.1)0.1MorphineInfusion, dose before withdrawal of interventionsc0Infusion, dose after withdrawal of interventionsc01MorphineInfusion, dose after withdrawal of interventionsc1 (2.1)30Bolus dose after withdrawal of interventionsc1 (2.1)30Bolus dose after withdrawal of interventionsa5 (10.6)10.85 ± 6.8AlfentanilBolus dose after withdrawal of interventionsa1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventionsc15 (31.9)10.06 ± 5.8Infusion, dose after withdrawal of interventionsc16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventionsc4 (8.5)6.75 ± 6DexmedetomidineInfusion, dose before withdrawal of interventionsc16 (34.5)1.2 ± 0.2		Bolus dose after withdrawal of interventions ^a	9 (19.2)	0.23 ± 0.2
Infusion, dose after withdrawal of interventions°19 (40.4)2.23 ± 1.2Bolus dose after withdrawal of interventionsa3 (6.3)64 ± 48.9RemifentanilInfusion, dose before withdrawal of interventionse1 (2.1)0.05Infusion, dose after withdrawal of interventionse1 (2.1)0.1MorphineInfusion, dose before withdrawal of interventionse0Infusion, dose after withdrawal of interventionse0	Propofol	Infusion, dose before withdrawal of interventions ^c	20 (42.6)	2.42 ± 1
Bolus dose after withdrawal of interventionsa3 (6.3)64 ± 48.9RemifentanilInfusion, dose before withdrawal of interventionse1 (2.1)0.05Infusion, dose after withdrawal of interventionse1 (2.1)0.1MorphineInfusion, dose before withdrawal of interventionse0Infusion, dose after withdrawal of interventionse01 (2.1)MorphineInfusion, dose after withdrawal of interventionse1 (2.1)30Bolus dose after withdrawal of interventionsa5 (10.6)10.85 ± 6.8AlfentanilBolus dose after withdrawal of interventionsa1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventionse15 (31.9)10.06 ± 5.8Infusion, dose after withdrawal of interventionsa16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventionsa4 (8.5)6.75 ± 6DexmedetomidineInfusion, dose before withdrawal of interventionsa4 (8.5)1.2 ± 0.2		Infusion, dose after withdrawal of interventions ^c	19 (40.4)	2.23 ± 1.2
RemifentanilInfusion, dose before withdrawal of interventionse1 (2.1)0.05Infusion, dose after withdrawal of interventionse1 (2.1)0.1MorphineInfusion, dose before withdrawal of interventionsc0Infusion, dose after withdrawal of interventionsc01 (2.1)Bolus dose after withdrawal of interventionsc1 (2.1)30Bolus dose after withdrawal of interventionsa5 (10.6)10.85 ± 6.8AlfentanilBolus dose after withdrawal of interventionsa1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventionsc15 (31.9)10.06 ± 5.8Infusion, dose after withdrawal of interventionsc16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventionsa4 (8.5)6.75 ± 6DexmedetomidineInfusion, dose before withdrawal of interventionsb4 (8.5)1.2 ± 0.2		Bolus dose after withdrawal of interventions ^a	3 (6.3)	64 ± 48.9
MorphineInfusion, dose after withdrawal of interventionse1 (2.1)0.1MorphineInfusion, dose before withdrawal of interventionsc00Infusion, dose after withdrawal of interventionsc1 (2.1)30Bolus dose after withdrawal of interventionsa5 (10.6)10.85 ± 6.8AlfentanilBolus dose after withdrawal of interventionsa1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventionsc15 (31.9)10.06 ± 5.8Infusion, dose after withdrawal of interventionsc16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventionsa4 (8.5)6.75 ± 6DexmedetomidineInfusion, dose before withdrawal of interventionsb4 (8.5)1.2 ± 0.2	Remifentanil	Infusion, dose before withdrawal of interventions ^e	1 (2.1)	0.05
MorphineInfusion, dose before withdrawal of interventions°0Infusion, dose after withdrawal of interventions°1 (2.1)30Bolus dose after withdrawal of interventionsa5 (10.6)10.85 ± 6.8AlfentanilBolus dose after withdrawal of interventionsa1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventionsc15 (31.9)10.06 ± 5.8Infusion, dose after withdrawal of interventionsc16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventionsc4 (8.5)6.75 ± 6DexmedetomidineInfusion, dose before withdrawal of interventionsc4 (8.5)1.2 ± 0.2		Infusion, dose after withdrawal of interventions ^e	1 (2.1)	0.1
Infusion, dose after withdrawal of interventionsc1 (2.1)30Bolus dose after withdrawal of interventionsa5 (10.6)10.85 ± 6.8AlfentanilBolus dose after withdrawal of interventionsa1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventionsc15 (31.9)10.06 ± 5.8Infusion, dose after withdrawal of interventionsc16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventionsa4 (8.5)6.75 ± 6DexmedetomidineInfusion, dose before withdrawal of interventionsb4 (8.5)1.2 ± 0.2	Morphine	Infusion, dose before withdrawal of interventions ^c	0	
Bolus dose after withdrawal of interventionsa5 (10.6)10.85 ± 6.8AlfentanilBolus dose after withdrawal of interventionsa1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventionsc15 (31.9)10.06 ± 5.8Infusion, dose after withdrawal of interventionsc16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventionsa4 (8.5)6.75 ± 6DexmedetomidineInfusion, dose before withdrawal of interventionsb4 (8.5)1.2 ± 0.2		Infusion, dose after withdrawal of interventions ^c	1 (2.1)	30
AlfentanilBolus dose after withdrawal of interventionsa1 (2.1)2.5MidazolamInfusion, dose before withdrawal of interventionsc15 (31.9)10.06 ± 5.8Infusion, dose after withdrawal of interventionsc16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventionsa4 (8.5)6.75 ± 6DexmedetomidineInfusion, dose before withdrawal of interventionsb4 (8.5)1.2 ± 0.2		Bolus dose after withdrawal of interventions ^a	5 (10.6)	10.85 ± 6.8
MidazolamInfusion, dose before withdrawal of interventionsc15 (31.9)10.06 ± 5.8Infusion, dose after withdrawal of interventionsc16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventionsa4 (8.5)6.75 ± 6DexmedetomidineInfusion, dose before withdrawal of interventionsb4 (8.5)1.2 ± 0.2	Alfentanil	Bolus dose after withdrawal of interventions ^a	1 (2.1)	2.5
Infusion, dose after withdrawal of interventionsc16 (34)10.19 ± 5.6Bolus dose after withdrawal of interventionsa4 (8.5)6.75 ± 6DexmedetomidineInfusion, dose before withdrawal of interventionsb4 (8.5)1.2 ± 0.2	Midazolam	Infusion, dose before withdrawal of interventions ^c	15 (31.9)	10.06 ± 5.8
Bolus dose after withdrawal of interventionsa4 (8.5)6.75 ± 6DexmedetomidineInfusion, dose before withdrawal of interventionsb4 (8.5)1.2 ± 0.2		Infusion, dose after withdrawal of interventions ^c	16 (34)	10.19 ± 5.6
Dexmedetomidine Infusion, dose before withdrawal of interventions ^b 4 (8.5) 1.2 ± 0.2		Bolus dose after withdrawal of interventions ^a	4 (8.5)	6.75 ± 6
	Dexmedetomidine	Infusion, dose before withdrawal of interventions ^b	4 (8.5)	1.2 ± 0.2
Infusion, dose after withdrawal of interventions ^b 4 (8.5) 1.05 \pm 0.7		Infusion, dose after withdrawal of interventions ^b	4 (8.5)	1. 05 ± 0.7
Diazepam Bolus dose after withdrawal of interventions ^a 1 (2.1) 17.75	Diazepam	Bolus dose after withdrawal of interventions ^a	1 (2.1)	17.75
RobinulBolus dose after withdrawal of interventions ^a 3 (6,3)0,33 ± 0,2	Robinul	Bolus dose after withdrawal of interventions ^a	3 (6,3)	0,33 ± 0,2

a = milligram b = microgram per kilogram per hour c = milligram per hour d = microgram per kilogram per hour e = microgram per kilogram per minute The average is also given for individual observations of medications to show dose/quantity. Abbreviations: SD = standard deviation

Communication with patients and their families

No conversations with the conscious patients were documented by nurses or doctors. In relation to all of the patients, conversations with their families were documented by doctors in 94.2% of cases and by ICU nurses in 65.2% of cases (Figure 1). The majority of patients had family members present when interventions were withdrawn (74%).



Figure 1. Communication with the families of all patients, and communication with conscious patients

The figure shows that there was documented information provided to conscious patients about the possible course of illness and expected prognosis, and that there were documented conversations conducted with patients' families.

Discussion

The study showed that there was inadequate documentation of pain assessment and nursing care plans. For conscious ICU patients there was, in addition, inadequate documentation of information provided when life-sustaining interventions were withdrawn.

Pain assessment

In this study, pain assessment was not documented for any of the conscious patients and only for about half of the unconscious patients. In the national clinical guidelines (9), regular observation of the patient's clinical condition is recommended to achieve good symptom management. Moreover, the local guidelines for pain assessment in the ICU stipulate that patients are to be assessed using NRS or CPOT once per shift and otherwise as required. The results are consistent with the findings from other studies (18, 19), which show that a low percentage of ICU patients have documented pain assessment.

The findings are surprising since carrying out systematic symptom assessments using validated tools is a prerequisite for good quality management of distressing symptoms in dying patients, for both conscious and sedated patients (14, 20). This study did not examine the reasons why pain assessment was poorly documented. One possible reason may be that the ICU nurse had asked the patient without documenting the response, or that the ICU nurse had perceived the patient as being so deeply sedated or comatose that they thought it was unnecessary to assess them using CPOT.

The results show, however, that analgesics were administered to patients without documented pain assessment as frequently as to patients with documented pain assessment. Regardless, ICU nurses should document the assessments they make (17), and the possibility cannot be ruled out that patients have experienced pain that has been overlooked due to a lack of systematic assessment and documentation.

Nursing care plans

In our study, only 13% of the patients had a documented nursing care plan. The national clinical guidelines stipulate that a nursing care plan for the withdrawal of life-sustaining interventions as well as anticipated needs for medication should be documented in patients' medical records. Earlier studies (21, 22) have shown that ICU nurses prefer a written nursing care plan in order to provide the best possible end-of-life care for patients.

One study (23) found that nurses regarded a nursing care plan as a useful tool. Another study (24) found that a lack of clear guidelines for the withdrawal of life-sustaining interventions resulted in ICU nurses being uncertain as to what were the correct interventions after withdrawal. One possible problem with using nursing care plans was that standardised plans were a barrier to individualised patient care.

A possible explanation as to why only nine of the patients had a documented nursing care plan was that ICU nurses can notify doctors when symptoms arise, and interventions and medications can then be administered on an ongoing basis. This is possible in ICUs where a doctor is present at all times. It is also likely that the doctor and the ICU nurse in many cases discussed a plan without registering this in the patient's medical records. In addition, the necessity of a nursing care plan is debatable when the median time from the withdrawal of interventions until death is 12 minutes. A Dutch observational study (27), in which the median time from withdrawal of interventions until death was 20 minutes, concluded however that a new guideline with advice on prevention of distressing symptoms was effective, and that most of the patients had a low symptom burden. If this is the case, nursing care plans will be of use even though there is only a short period of time between the withdrawal of interventions and death.

Medication-based management of distressing symptoms

The results of our study showed that there was no increase in medication doses before and after withdrawal of interventions in sedated patients, apart from two patients who were given morphine and remiferitanil respectively in addition. This finding contrasts with several other studies that found that doses of opioids were increased when life-sustaining interventions for ICU patients were withdrawn (27–29).

There are several possible explanations for this variation. A guideline or individual nursing plan for the withdrawal of life-sustaining interventions can make it easier for ICU nurses to increase doses of analgesics and sedatives. This correlates with the findings of the Dutch observational study (27), which found that when a new national protocol for end-of-life care was introduced, the use of midazolam, propofol and opioids increased significantly.

Furthermore, the patients in our study may have been more heavily sedated to begin with than those in the other studies, such that it was not necessary to increase the medication dose. We did not collect data on depth of sedation, so we cannot compare the level of sedation in the course of care. In addition, the time from withdrawal of interventions until death was 12 minutes in our study.

Experience suggests that with such short time intervals, the choice is often made to administer bolus doses based on need, which a number of the patients in our study received. When the median time is only 12 minutes, it may indicate that the patients' conditions are so critical that they are already in the advanced stages of dying when interventions are withdrawn and do not, therefore, have a greater need for palliative medications. However, in the studies from the Netherlands (27) and the United States (28), in which the median time interval from withdrawal of interventions until death was 20 minutes and 42 minutes respectively, there was a substantial increase in medication doses.

Less than half of the comatose patients were given analgesics, and a sixth received medications for anxiety and agitation. This finding corresponds to the US study (28), which showed that comatose patients were given less morphine than other patients. It may be that analgesics are not administered to comatose patients who do not respond to pain stimuli because it is assumed that they do not feel pain.

The experience of pain is subjective (30), and when there is no reaction to pain stimuli it is likely that there is little need for analgesics. Therefore, it is not surprising that comatose patients are given lower doses than other patients. For neurocritically ill patients with a minimum level of consciousness who may experience pain that they are unable to communicate, it is, on the other hand, important that ICU nurses observe signs of discomfort and administer sufficient levels of analgesics (30, 31).

An interesting finding was that patients with a decreased level of consciousness and conscious patients only received bolus doses of symptom relief medications, and the doses administered were low. Only one patient received non-opioid analgesics. It is therefore difficult to compare with other studies in which patients received continual infusions of medication (27, 28).

It may be assumed that in the case of extreme deterioration of conscious patients, it was more practical to administer analgesics based on need. In addition, there was a lack of documented pain assessment using NRS and CPOT, which makes it difficult to know the actual symptom burden and need for palliative medications. Experience indicates that some ICU nurses and doctors can be reluctant to give opioids to dying patients for fear of adverse effects such as respiratory depression and hypotension. There is little evidence to support this practice, since a number of studies show that the increased use of opioids can extend the time from withdrawal of interventions until death (27–29).

Communication with patients and their families

A total of 94.2% of patients' families had had conversations with the doctor, which is a high level compared with a study from the United States (32), which found that interdisciplinary meetings with patients' families were documented in less than 20% of cases. Conversations with patients' families is important, since the time between critical illness and death is short in an ICU.

One study (33) showed that clear and honest communication was a factor that affected the satisfaction of patients' families when the patient was in the end-of-life period, and it helped to prevent post-traumatic stress among family members. The national clinical guidelines (9) stipulate that healthcare personnel are to ensure that the needs of patients and their families for conversations and information during the end-of-life period are met, but our study only examined whether conversations were documented. We did not examine the content of the information that was provided, nor whether patients' families felt that they had received sufficient information.

No conversations in which patients were given information about the possible course of illness and expected prognosis were documented by ICU nurses or doctors with the four conscious patients. This is an interesting finding because patients have a right to information regarding the condition of their health (34).

Our study only examined the documented practice. It is to be hoped that conversations were carried out with patients without this being documented in their medical records. Nevertheless, it is unfortunate that there was no documentation of the information provided to patients, or in relation to whether the situation made it impossible to provide information.

The patient must be given continuous updates on their condition and, if possible, participate in decision-making processes in conjunction with the withdrawal of life-sustaining interventions (9). If not, this may result in a failure to clarify the patient's wishes, such as the need for religious rituals or ideas about how the withdrawal should be carried out, or that the patient lacks assurance that pain and discomfort will be relieved.

In our study, only four of the patients were categorised as conscious, so we are unable to conclude this with any certainty. Nevertheless, the finding indicates that the practice of providing information to conscious patients who are critically ill in ICUs must be studied further.

Strengths and weaknesses of the study

One weakness of the study is that it was retrospective and only examined documented practices, which means that assessments and interventions may have been carried out that were not documented. Another weakness was that the patients who did not die in the ICU after the withdrawal of interventions but were transferred to a ward were not included. Information about what palliative care they received prior to being transferred would have been relevant to the study.

It is also a weakness that the sample only came from one ICU, which limits generalisation. The results do not necessarily represent other ICUs, which may have their own internal guidelines and routines.

A significant strength of the retrospective design is that we avoided bias, in that none of the nurses or doctors in the ICU knew that the data were going to be used for this purpose. Therefore, they could not influence the results (12).

Conclusion

The study shows that there was inadequate documentation of pain assessment, nursing care plans and information provided to dying ICU patients, if documented practice is to be in accordance with the national clinical guidelines for palliative care during the end-of-life period.

A particularly important finding was that there was no documentation of information to any of the conscious patients. The findings in the study highlight that it is important to be aware of palliative care for ICU patients, to ensure good routines for pain assessment and for planning end-of-life symptom management.

The authors declared no conflicts of interest.

Open access <u>CC BY 4.0</u>.



PALLIATIVE CARE: Many dying patients in intensive care have a high sympto... READ MORE \checkmark

1. Mercadante S, Gregoretti C, Cortegiani A. Palliative care in intensive care units: why, where, what, who, when, how. BMC Anesthesiology. 2018;18(1):106. DOI: 10.1186/s12871-018-0574-9

2. Buanes EA, Kvåle R, Helland KF, Barrat-Due A. Norsk intensiv- og pandemiregister. Årsrapport for 2021 med plan for forbetringstiltak. Bergen: Helse Bergen, Norsk intensivregister; 2022. Available at: <u>https://helse-</u>

bergen.no/seksjon/intensivregister/Documents/Årsrapporter i NIR/NIPaR Årsrapport 2021.pdf (downloaded 05.09.2022).

3. NSFs Landsgruppe av intensivsykepleiere. Funksjons- og ansvarsbeskrivelse for intensivsykepleier. Oslo: NSF; 2017. Available at:

https://www.nsf.no/sites/default/files/inline-

<u>images/czwgg4sqZCCRzfiNDM56nSWsxIgGCkwVuoUe0fcXZ6NYPysIQb.pdf</u> (downloaded 20.09.2021).

4. Puntillo KA, Arai S, Cohen NH, Gropper MA, Neuhaus J, Paul SM, et al. Symptoms experienced by intensive care unit patients at high risk of dying. Crit Care Med. 2010;38(11):2155–160. DOI: <u>10.1097/CCM.0b013e3181f267ee</u>

5. Puntillo K, Nelson JE, Weissman D, Curtis R, Weiss S, Frontera J, et al. Palliative care in the ICU: relief of pain, dyspnea, and thirst – a report from the IPAL-ICU Advisory Board. Intensive Care Med. 2014;40(2):235–48. DOI: <u>10.1007/s00134-013-3153-z</u>

6. Wilkie DJ, Ezenwa MO. Pain and symptom management in palliative care and at end of life. Nurs Outlook. 2012;60(6):357–64. DOI: <u>10.1016/j.outlook.2012.08.002</u>

7. Curtis JR, Vincent J-L. Ethics and end-of-life care for adults in the intensive care unit. Lancet. 2010;376(9749):1347–53. DOI: <u>10.1016/S0140-6736(10)60143-2</u>

8. Alshehri HH, Olausson S, Öhlén J, Wolf A. Factors influencing the integration of a palliative approach in intensive care units: a systematic mixed-methods review. BMC Palliat Care. 2020;19(1):1–18. DOI: <u>10.1186/s12904-020-00616-y</u>

9. Helsedirektoratet. Nasjonale faglige råd for lindrende behandling i livets sluttfase. Oslo: Helsedirektoratet; 2018. Available at: <u>https://www.helsedirektoratet.no/faglige-</u> <u>rad/lindrende-behandling-i-livets-sluttfase</u> (downloaded 09.08.2021).

10. Lov 2. juli 1999 nr. 61 om spesialisthelsetjenesten (spesialisthelsetjenesteloven). Available at: <u>https://lovdata.no/dokument/NL/lov/1999-07-02-61/KAPITTEL_2#§2-1a</u>. (downloaded 05.06.2022).

11. NOU 2017: 16. På liv og død – palliasjon til alvorlig syke og døende. Oslo: Helse- og omsorgsdepartementet; 2017. Available at: <u>https://www.regjeringen.no/contentassets/995cf4e2d4594094b48551eb381c533e/nou-2017-16-pa-liv-og-dod.pdf</u> (downloaded 28.03.2022).

12. Polit DF, Beck CT. Nursing research. Generating and assessing evidence for nursing practice. 11th ed. Philadelphia, Pennsylvania: Wolters Kluwer; 2021.

13. Helsebiblioteket. Evaluere praksis. Oslo: Helsebiblioteket; 2021. Available at: <u>https://www.helsebiblioteket.no/kunnskapsbasert-praksis/evaluere-praksis</u> (downloaded 26.11.2021).

14. Keane KM. Validity and reliability of the Critical Care Pain Observation Tool: a replication study. Pain Manag Nurs. 2013;14(4):e216–25. DOI: <u>10.1016/j.pmn.2012.01.002</u>

15. Ely EW, Truman B, Shintani A, Thomason JWW, Wheeler AP, Gordon S, et al. Monitoring sedation status over time in ICU patients reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA. 2003;289(22):2983–91. DOI: <u>10.1001/jama.289.22.2983</u>

16. IBM. SPSS Statistics for Windows, version 27. New York: IBM; n.d.

17. Lov 2. juli 1999 nr. 64 om helsepersonell (helsepersonelloven). Available at: <u>https://lovdata.no/dokument/NL/lov/1999-07-02-64</u> (downloaded 05.06.2022).

18. Wysham NG, Hochman MJ, Wolf SP, Cox CE, Kamal AH. Performance of consultative palliative care model in achieving quality metrics in the ICU. J Pain Symptom Manage. 2016;52(6):873–77. DOI: <u>10.1016/j.jpainsymman.2016.05.026</u>

19. Burry LD, Williamson DR, Perreault MM, Rose L, Cook DJ, Ferguson ND, et al. Analgesic, sedative, antipsychotic, and neuromuscular blocker use in Canadian intensive care units: a prospective, multicentre, observational study. Can J Anesth. 2014;61(7):619– 30. DOI: <u>10.1007/s12630-014-0174-1</u>

20. Mularski RA, Puntillo K, Varkey B, Erstad BL, Grap MJ, Gilbert HC, et al. Pain management within the palliative and end-of-life care experience in the ICU. Chest. 2009;135(5):1360–69. DOI: <u>10.1378/chest.08-2328</u>

21. Ong KK, Ting KC, Chow YL. The trajectory of experience of critical care nurses in providing end-of-life care: a qualitative descriptive study. J Clin Nurs. 2018;27(1–2):257–68. DOI: <u>10.1111/jocn.13882</u>

22. Hansen L, Goodell TT, DeHaven J, Smith M. Nurses' perceptions of end-of-life care after multiple interventions for improvement. Am J Crit Care. 2009;18(3):263–71. DOI: 10.4037/ajcc2009727

23. Brooks LA, Manias E, Nicholson P. Communication and decision-making about end-of-life care in the intensive care unit. Am J Crit Care. 2017;26(4):336–41. DOI: 10.4037/ajcc2017774

24. Efstathiou N, Walker W. Intensive care nurses' experiences of providing end-of-life care after treatment withdrawal: a qualitative study. J Clin Nurs. 2014;23(21–22):3188–96. DOI: <u>10.1111/jocn.12565</u>

25. Luckett A. End-of-life care guidelines and care plans in the intensive care unit. Br J Nurs. 2017;26(5):287–93. DOI: <u>10.12968/bjon.2017.26.5.287</u>

26. Radcliffe C, Hewison A. Use of a supportive care pathway for end-of-life care in an intensive care unit: a qualitative study. Int J Palliat Nurs. 2015;21(12):608–15. DOI: <u>10.12968/ijpn.2015.21.12.608</u>

27. Epker JL, Bakker J, Lingsma HF, Kompanje EJO. An observational study on a protocol for withdrawal of life-sustaining measures on two non-academic Intensive Care Units in the Netherlands: Few signs of distress, no suffering? J Pain Symptom Manage. 2015;50(5):676–84. DOI: <u>10.1016/j.jpainsymman.2015.05.017</u>

28. Mazer MA, Alligood CM, Wu Q. The infusion of opioids during terminal withdrawal of mechanical ventilation in the medical intensive care unit. J Pain Symptom Manage. 2011;42(1):44–51. DOI: <u>10.1016/j.jpainsymman.2010.10.256</u>

29. Laserna A, Durán-Crane A, López-Olivo MA, Cuenca JA, Fowler C, Díaz DP, et al. Pain management during the withholding and withdrawal of life support in critically ill patients at the end-of-life: a systematic review and meta-analysis. Int Care Med. 2020;46(9):1671–82. DOI: <u>10.1007/s00134-020-06139-7</u> 30. Schnakers C, Chatelle C, Majerus S, Gosseries O, De Val M, Laureys S. Assessment and detection of pain in noncommunicative severely brain-injured patients. Expert Rev Neurother. 2010;10(11):1725–31. DOI: <u>10.1586/ern.10.148</u>

31. Frontera JA, Curtis JR, Nelson JE, Campbell M, Gabriel M, Hays RM, et al. Integrating palliative care into the care of neurocritically ill patients: a report from the IPAL-ICU (improving palliative care in the intensive care unit) project advisory board and the center to advance palliative care. Crit Care Med. 2015;43(9):1964–77. DOI: <u>10.1097/CCM.00000000001131</u>

32. Penrod JD, Pronovost PJ, Livote EE, Puntillo KA, Walker AS, Wallenstein S, et al. Meeting standards of high-quality intensive care unit palliative care: clinical performance and predictors. Crit Care Med. 2012;40(4):1105–12. DOI: <u>10.1097/CCM.0b013e3182374a50</u>

33. Jensen HI, Halvorsen K, Jerpseth H, Fridh I, Lind R. Practice recommendations for end-of-life care in the Intensive Care Unit. Crit Care Nurse. 2020;40(3):14–22. DOI: 10.4037/ccn2020834

34. Lov 2. juli 1999 nr. 63 om pasient- og brukerrettigheter (pasient- og brukerrettighetsloven). Available at: <u>https://lovdata.no/dokument/NL/lov/1999-07-02-63</u> (downloaded 10.10.2022).